To enact section 125.62 of the Revised Code to establish the Ohio-Made Medicine Manufacturing Program and to name this act the Ohio-Made Prescription Drug Act.
HB892 would create the Ohio-Made Medicine Manufacturing Program within the Ohio Department of Administrative Services, with the Departments of Health and Development providing expertise and staffing support. The program is intended to make essential drugs more affordable by supporting the distribution, manufacture, purchase, or sale of generically equivalent drugs, with a particular focus on lowering costs, increasing competition, and addressing shortages in the prescription drug market.
The bill directs the program administrator to identify target generic drugs, form partnerships with state agencies, payers, hospitals, pharmacy benefit managers, group purchasing organizations, nonprofit corporations, and other entities, and in some cases set transparent prices for drugs sold through the program. It also requires annual reporting to the governor and General Assembly on the program’s status, market impact, and recommended improvements, and it protects program-related cost and pricing information from public records disclosure.
If enacted, HB892 would add a new section to the Revised Code and create a state-run framework for intervening in the generic drug market. It would give the Department of Administrative Services a central role in coordinating with health and economic development agencies to pursue partnerships aimed at manufacturing, purchasing, or distributing lower-cost generic medicines, while also setting rules for drug selection, pricing, and reporting. The bill would affect state agencies that purchase drugs, state retirement systems, health plan issuers, hospitals, pharmacy benefit managers, and potentially drug manufacturers and distributors that partner with the state.
The bill’s stated purpose and structure suggest a generally pro-affordability, pro-competition approach to prescription drug pricing, with emphasis on lowering costs for consumers, taxpayers, and public purchasers. Because the bill was only introduced and no committee testimony or votes are provided, there is no recorded legislative debate in the supplied materials. The available context therefore indicates policy interest in drug affordability, but not a documented level of support or opposition from lawmakers.
The main points of potential contention are the state’s role in the drug market, the use of public resources to create partnerships or manufacturing arrangements, and the authority of the administrator to set prices for certain drugs. Stakeholders such as pharmacy benefit managers, health plan issuers, hospitals, manufacturers, and public purchasers could differ on whether the program would meaningfully reduce costs or instead create administrative complexity and market distortions. The bill also raises transparency concerns by exempting program-related pricing and cost information from public records, which may be viewed as necessary to protect proprietary data or as limiting public oversight.